Allspring Global Investments Holdings LLC Decreases Position in LivaNova PLC (NASDAQ:LIVN)

Allspring Global Investments Holdings LLC trimmed its holdings in LivaNova PLC (NASDAQ:LIVN - Free Report) by 3.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 772,132 shares of the company's stock after selling 25,152 shares during the period. Allspring Global Investments Holdings LLC owned about 1.42% of LivaNova worth $35,757,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Point72 Asset Management L.P. grew its stake in LivaNova by 62.7% in the third quarter. Point72 Asset Management L.P. now owns 2,092,010 shares of the company's stock valued at $109,914,000 after acquiring an additional 806,374 shares during the period. Geode Capital Management LLC grew its stake in LivaNova by 0.6% in the third quarter. Geode Capital Management LLC now owns 1,344,949 shares of the company's stock valued at $70,676,000 after acquiring an additional 8,331 shares during the period. Victory Capital Management Inc. grew its stake in LivaNova by 16.6% in the third quarter. Victory Capital Management Inc. now owns 935,102 shares of the company's stock valued at $49,130,000 after acquiring an additional 133,401 shares during the period. Emerald Advisers LLC grew its stake in LivaNova by 2.1% in the third quarter. Emerald Advisers LLC now owns 695,505 shares of the company's stock valued at $36,542,000 after acquiring an additional 14,302 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its stake in LivaNova by 17.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 621,959 shares of the company's stock valued at $32,678,000 after acquiring an additional 93,311 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

LivaNova Stock Down 1.0 %

LIVN stock traded down $0.49 during mid-day trading on Tuesday, reaching $47.19. 164,351 shares of the company traded hands, compared to its average volume of 435,692. The stock has a market cap of $2.56 billion, a price-to-earnings ratio of 112.29 and a beta of 1.00. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. LivaNova PLC has a fifty-two week low of $43.15 and a fifty-two week high of $64.47. The firm's 50 day moving average price is $48.25 and its 200 day moving average price is $49.55.

Insider Transactions at LivaNova

In other LivaNova news, Director Francesco Bianchi sold 1,250 shares of the business's stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total value of $63,737.50. Following the sale, the director now directly owns 7,522 shares in the company, valued at $383,546.78. The trade was a 14.25 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 0.27% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on LIVN. StockNews.com raised LivaNova from a "buy" rating to a "strong-buy" rating in a research report on Friday. Mizuho reduced their price objective on LivaNova from $80.00 to $70.00 and set an "outperform" rating for the company in a research report on Thursday, October 31st. Robert W. Baird upped their price objective on LivaNova from $66.00 to $72.00 and gave the stock an "outperform" rating in a research report on Thursday, October 31st. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $75.00 price objective on shares of LivaNova in a research report on Tuesday, January 28th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, LivaNova has a consensus rating of "Buy" and an average target price of $69.17.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.